Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 8/20 | 0.35 |
| ▸ | CDK2 | P24941 | 8/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | HTR1F | P30939 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25884472 | 0.87 | ALOX15 (0.50) | ALOX15GAASMN1; SMN2CDK9CDK2 | |
| SCHEMBL25889738 | 0.84 | ALOX15 (0.56) | ALOX15GAASMN1; SMN2CDK2HTR1A | |
| SCHEMBL21907124 | 0.75 | HSP90AA1 (0.35) | ALOX15 | |
| SCHEMBL23325064 | 0.75 | CYP2C19 (0.32) | ALOX15 | |
| SCHEMBL25931498 | 0.75 | CYP2C19 (0.32) | — | |
| SCHEMBL24127530 | 0.71 | ALOX15 (0.47) | ALOX15GAASMN1; SMN2CDK2HTR1A | |
| SCHEMBL19203134 | 0.65 | ALOX15 (0.38) | ALOX15 | |
| SCHEMBL25463364 | 0.65 | PDE9A (0.33) | ALOX15 | |
| SCHEMBL22789033 | 0.64 | CYP11B1 (0.36) | ALOX15 | |
| SCHEMBL21266802 | 0.64 | ALOX15 (0.70) | ALOX15GAASMN1; SMN2HTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ALOX15 4589/4885GAA 2164/4885SMN1; SMN2 3728/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ALOX15 3782/4885GAA 905/4885SMN1; SMN2 1139/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALOX15 4589/4885GAA 2164/4885SMN1; SMN2 3728/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALOX15 4589/4885GAA 2164/4885SMN1; SMN2 3728/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALOX15 4589/4885GAA 2164/4885SMN1; SMN2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.